drugs

Hepatitis C, a Silent Killer, Meets Its Match

Posted November 24th, 2013 by admin
in

Over the next three years, starting within the next few weeks, new drugs are expected to come to market that will cure most patients with the virus, in some cases with a once-a-day pill taken for as little as eight weeks, and with only minimal side effects.

That would be a vast improvement over current therapies, which cure about 70 percent of newly treated patients but require six to 12 months of injections that can bring horrible side effects.

Russia develops effective drug to treat hepatitis C

Posted October 30th, 2013 by admin
in

Russian scientists have developed an innovative drug that can cure hepatitis C within a month. They started their research in this area over 20 years ago and at present, they have patented the drug which will be available for sale next year.

Patient Dilemma: Treat Hepatitis C Now or Hold Out?

Posted March 14th, 2013 by admin
in

Being diagnosed with a potentially fatal disease usually triggers immediate treatment. But a growing number of people infected with hepatitis C are putting off therapy, choosing instead to roll the dice and wait for a new generation of drugs to become available.

FDA Breaks Promise on Proposed New Supplement Rules

Posted May 25th, 2012 by admin
in

FDA promised not to enforce the NDI guidance until it was final. Last Friday, they broke that promise.

I can’t express my appreciation enough!

Posted March 19th, 2012 by admin
in

Sent: Friday, March 16, 2012 4:03 PM
To: Lloyd Wright
Subject:

Lloyd,

Was just getting ready to order VEP 2 and a tea package in the next day or so. As it happens, I was with a close friend of mine who is sick and in a similar condition. Maybe worse, since he has diabetes. And doesn’t eat or exercise obsessively, as I do.

And we always try and exchange any information we come across. So, we went online and I was showing him a couple of your Youtube interviews about the various Teas and the “do not take” items.

Gilead Says Hepatitis C Patients Had Relapse in Trial, Shares Plunge

Posted February 21st, 2012 by admin
in

Shares of Gilead Sciences (GILD: 44.69, -2.31, -4.91%) fell 14% Friday morning after the drug maker said a majority of patients enrolled in one of its studies experienced a viral relapse within four weeks of completing the 12-week experimental hepatitis C treatment.

Six of the eight patients that previously had a “null” response but were taking GS-7977 plus the widely used antiviral ribavirin as part of Gilead’s Electron study had a relapse.

Confessions of a Frustrated Pharmacist

Posted February 6th, 2012 by admin
in

by Stuart Lindsey, PharmD.

When an insider breaks ranks with pharmaceutical orthodoxy, it is time to take notice. "Whistleblower" may be an overused term, but the article that follows might be well worth readers' consideration before standing in line for their next prescription refill. - Andrew W. Saul, OMNS Editor

Some new information on the oral hep c drugs in the pipe line.

Posted January 16th, 2012 by admin
in

Yesterday, January 9, 2012 Inhibitex, makers of an oral hep c drug was purchased by Bristol Myers for 2.5 Billion dollars.

On Squawk Box, CNBC,  Kramer said, I don’t get it, hep c is a horrible disease, it is fatal but not a big deal. He said, I don’t get it, why so much money is being paid for this oral phase 2 asset. Inhibitex stock went up 189 times over night. A terrific profit.

Russia develops effective drug to treat hepatitis C

Posted November 25th, 2011 by admin
in

Russian scientists have developed an innovative drug that can cure hepatitis C within a month. They started their research in this area over 20 years ago and at present, they have patented the drug which will be available for sale next year.

The drug known as Profetal is based on human alpha-fetoprotein, says Alexander Petrov, head of the Ural Pharmaceutics Cluster, where the project is underway, in an interview with the Voice of Russia.